 - Patients must have histologically confirmed diagnosis of malignant glioma and radiographic evidence of recurrence or disease progression defined as either a greater than 25 increase in the largest bidimensional product of enhancement or a new enhancing lesion following prior therapy. In addition, the following must be met: 